Pathological Response After Neoadjuvant Chemotherapy And... comparing neoadjuvant to adjuvant chemotherapy had concluded that neoadjuvant chemotherapy was apparently equivalent to adjuvant therapy in terms of disease free survival and overall survival 6 . However, in two large studies by the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 and B-27, subgroup analysis of patients experiencing a pathologic complete response (pCR) of invasive tumours showed a significantly prolonged overall survival 7, 8 .
Most studies on the use of trastuzumab in a neoadjuvant setting have been single-arm studies without acomparator 9 .
Buzdar et al. 10 . compared neoadjuvant 5-fluorouracil/ epirubicin/cyclophosphamide and paclitaxel chemotherapy with or without trastuzumab for the treatment of HER2-postive, operable breast cancer. The pathological complete remission (pCR) rate, which was the primary endpoint, was strikingly superior in the chemotherapy plus trastuzumab arm, when compared with that in the chemotherapy-alone arm (65% vs. 26%, P ¼ 0.016). Chang et al. 11 . Conducted a randomized study comparing neoadjuvant docetaxel/carboplatin (DC) therapy with or without trastuzumab in women with locally advanced breast cancer. The pCR rate was 36.4% in the DC plus trastuzumab arm, in contrast to the rate of 9% in the DC-alone arm.
The current study aimed at evaluation of the pathological complete response (pCR), efficacy and safety of an anthracycline-taxane-cisplatinum-herceptin containing regimen as neoadjuvant chemotherapy in locally advanced HER 2 positive breast cancer. 12 . Complete response (CR) was defined as the disappearance of all known disease with no evidence of progressive disease; partial response (PR) was defined as a > 30% decrease in the sum of longest diameters of all target lesions with no appearance of new lesions. Progressive disease (PD) was defined as at least 20% increase in the sum of the longest diameters of all target lesions or the appearance of new lesions. Stable disease was defined neither as PR nor as PD.
PAtIEntS And MEtHodS

This
Pathological assessment
Tumor samples were collected by needle core biopsy or surgical biopsy prior to systemic chemotherapy. ER, PR and HER-2/neu, were determined by standard immunohistochemistry (IHC). Tumors with less than 1% stained cells were considered to have Negative receptor status. HER-2/neu status was assessed by IHC and by fluorescence in situ hyperdization (FISH) confirmation if 2+ immunohistochemistry staining was present. In our study, pathological response was considered complete (pCR) if no histological evidence of residual invasive or in situ tumor in all resected specimens of the breast and the axillary lymph nodes could be detected. Near complete pathological response (npCR) was considered if only occasionally scattered invasive tumor cells with a size of 5 mm or less in aggregates removed from the breast tissue at the time of definitive surgery.
treatment plan and follow up
Neoadjuvant chemotherapy consisted of 4 cycles of AC (60mg/m 2 ,600mg/m 2 ) followed by 4 cycles consisting of D-Cis (75mg/m 2 each) every 3 weeks. Trastuzumab (T) started with the first cycle of Docetaxel-Cisplatin at 8 mg/ Kg as loading dose then 6 mg /Kg for 1year. The cycles were given every 3 weeks. All patients provided written consent. Clinical response, complete blood count and chemistry were assessed with every cycle. Echocardiography was done every 3 months to assess LT ventricular ejection fraction during Herceptin therapy. Surgery was performed on day 28 after completion of preoperative chemotherapy. Adjuvant radiotherapy and hormaonal treatment was administered after surgery whenever indicated. After completion of the treatment plan, follow up was carried out every three months. Toxicity was assessed using the Common Toxicity Criteria Version 2 33 . Follow-up data are available for 31 patients. Local recurrence and distant failure were reported in 9 patients, of these, four occurred in patients with a pCR and five occurred in patients with residual invasive component.
At last follow up (Mach 2012) twenty one patients (67.7%) were alive free of the disease Table 4 . dIScuSSIon HER 2 overexpression occurs in approximately 20 to 25% of human breast cancers and is associated with an aggressive clinical phenotype that includes highgrade tumors, increased growth rates, early systemic metastases and decreased rates of disease-free and overall survival 13, 14 .
Preclinical data indicate that this adverse clinical picture results from fundamental changes in the biologic features of breast-cancer cells containing the alteration, including increased proliferation, suppression of apoptosis, increased motility, greater invasive and metastatic potential, accelerated angiogenesis, and steroid hormone independence [15] [16] [17] .
Many studies had shown that these HER2-mediated adverse characteristics were reversed by the use of monoclonal antibodies directed against the tyrosine kinase receptor [18] [19] [20] and these data led to phase 1 testing of a murine anti-HER2 monoclonal antibody 21 . Preliminary efficacy and safety data prompted the development of a humanized monoclonal antibody to produce trastuzumab 22 . Subsequently, in a large, randomized study, the addition of trastuzumab to chemotherapy yielded significant improvements in rates of objective response, response duration, and time to disease progression (56%, 58%, and 65% improvement, respectively), as well as a 30% improvement in the rate of overall survival among patients with first-line metastatic disease. A significant side effect was an increase by a factor of 4 in the rate of cardiac dysfunction, including congestive heart failure, especially when trastuzumab was used in combination with anthracycline-based regimens 23 .
Pre-operative systemic chemotherapy (PST) is the treatment of choice for women with locally advanced breast cancer 6 . It aims to reduce the tumor size and may allow for breast conserving.
surgery. Tumor response can be assessed clinically and pathologically and is valuable for testing new therapies. Pathological complete response (pCR) also provides a surrogate for disease-free and overall survival 24 . The rationale for integrating trastuzumab into PST for HER2-positive breast cancer is based on the association between HER2 overexpression and poor prognosis 25 . Trastuzumab binds selectively to the HER2 receptor, provides significant clinical benefits including a survival advantage when combined with standard chemotherapy in HER2-positive metastatic breast cancer 26 . Furthermore, when combined with docetaxel in patients with HER2-positive breast cancer, trastuzumab significantly improved all efficacy parameters, including overall survival, compared with docetaxel alone 23 .
In our study Trastuzumab plus neoadjuvant chemotherapy showed favorable safety and tolerability. No patients experienced symptomatic cardiac dysfunction. Only 3 patients had to interrupt treatment for a transient, asymptomatic decrease in LVEF and none of them had known risk factors for the cardiac dysfunction. The LVEF normalized 1 month after treatment was discontinued.
The overall clinical response rates observed in the current study appear very promising (96.8%), which is comparable with previously reported other studies using trastuzumab-containing combination chemotherapy regimens. The Neoadjuvant Herceptin (NOAH) trial reported an overall response rate of 89%
27 . In the current study the second sequence of chemotherapy with Docetaxel-Cisplatin-Trastuzumab almost doubled the rate of clinical complete response obtained with Adriamycin-Cyclophosphamide.
In our study, the pCR rate in both breast and axilla was 33.3% using the protocol predefined definition (excluding patients with remaining ductal carcinoma in situ) and 53.3% using the now widely used definition of no invasive residual tumor in the breast and lymph nodes. Other trials reported an incidence of pCR of 60%, 43% and 31.7% respectively [28] [29] [30] .
In the GeparQuattro and TECHNO trials the authors reported an incidence of 31.7% and 39%, respectively for pCR in patients who received Trastuzumab with neoadjuvant chemotherapy 31, 32 .
In our study, despite the high pCR ratedid not result in a higher rate of breast-conserving surgery and this may be attributed to high percentage of patients who presented initially with T4 stage (54.8%). Similar findings were reported in the GeparQuattro study 31 .
concLuSIonS
We have shown that the combination of trastuzumab with Adriamycin-Cyclophosphamide and DocetaxelCisplatin as neoadjuvant treatment of HER2-positive locally advanced breast cancer is active and well tolerated. The pathological complete response rate (pCR) in patients with HER 2 positive locally advanced breast cancer was 33.3%. As the sample size for this study was small, further assessment in a large trial is warranted.
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